Massive 60,000-Person study tests which diabetes drug best shields the heart
NCT ID NCT07417618
Summary
This study aims to see which of three newer diabetes medications (dulaglutide, semaglutide, and tirzepatide) works best to prevent serious heart problems like heart attacks and strokes in people with type 2 diabetes and overweight. It will analyze health insurance records from 60,000 people, comparing these drugs to an older one (sitagliptin), for those with and without existing heart disease. The goal is to provide real-world evidence to help doctors choose the most protective medication for their patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States
Conditions
Explore the condition pages connected to this study.